Abstract
Background: A prospective Phase II study of Taxol in young adult patients with recurrent anaplastic astrocytomas.
Methods: Twenty-four patients (15 men; 9 women) ages 19–45 years (median 31.5), with recurrent anaplastic astrocytomas were treated. All patients had previously been treated with surgery and involved-field radiotherapy (median dose 60 Gy; range 51–61 Gy). Additionally, 22 patients were treated adjuvantly with nitrosourea-based chemotherapy (PCV in 17; BCNU in 5). Fourteen patients were treated with salvage chemotherapy at first recurrence with 1–2 chemotherapy regimens (median 1). Taxol was administered at a fixed dose of 175 mg/m2 given as a 3 h intravenous infusion monthly. Neurological and neuroradiographic evaluation were performed every 8 weeks after 2 courses of Taxol, operationally defined as a single cycle of Taxol.
Results: All patients were evaluable. A median of 3.5 cycles of Taxol (range 1–13) were administered. Taxol-related toxicity included: partial alopecia (13 patients); non-disabling peripheral neuropathy (4); neutropenia (4); anemia (3); and thrombocytopenia (2). Four patients required transfusions (2 packed red blood cell; 2 platelet) and one patient was treated for culture negative neutropenic fever. No treatment-related deaths were observed. Three patients (13%) demonstrated a neuroradiographic partial response, 16 patients (67%) demonstrated stable disease and 5 patients (21%) had progressive disease following a single cycle of Taxol. Time to tumor progression ranged from 2–26 months (median 7.5 months). Nineteen patients were offered alternative chemotherapy after failing Taxol of whom 13 clinically responded. Survival ranged from 3–56 months (median 18.5 months). Four patients are alive, all are on alternative chemotherapy regimens.
Conclusions: Taxol demonstrated modest efficacy with manageable toxicity in this heavily pre-treated cohort of young adult patients with recurrent anaplastic astrocytomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shapiro WR, Green SB, Burger PC, et al.: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in post-operative treatment of malignant glioma. Brain tumor cooperative group trial 8001. J Neurosurg 71: 1–9, 1989
Black PMcL: Brain Tumors, Part I. Medical Progress 324(21): 1471–1476, 1991
Black PMcL: Brain Tumors, Part II. Medical Progress 324(22): 1555–1564, 1991
Gutin PH, Prados MD, Phillips TL, et al.: External irradiation followed by an interstitial high activity iodine-125 implant ‘boost’ in the initial treatment of malignant gliomas: NCOG Study 6G82-2. Int J Radiat Oncol Biol Phys 21: 601, 1991
Kornblith PD, Welch WC, Bradley MK: The future of therapy for glioblastoma. Surg Neurol 39: 538–543, 1993
Prados MD, Gutin PH, Phillips TL, et al.: Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: TheUCSFexperience. Int J Radiat Oncol Biol Phys 24: 593, 1992
Yung WKA, Mechtler L, Gleason MJ: Intravenous carboplatin for recurrent malignant gliomas: A phase II study. J Clin Oncol 9: 860, 1991
Allen JC, Walker R, Luks E, et al.: Carboplatin and recurrent childhood brain tumors. J Clin Oncol 5: 759–763, 1987
Loeffler JS, Alexander E, Shea WM, et al.: Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 10(9): 1379–1385, 1992
Levin VA, Silver P, Hannigan J, et al.: Superiority of Post-Radiotherapy Adjuvant Chemotherapy with CCNU, Procarbazine, and Vincristine (PCV) over BCNU for Anaplastic Gliomas:NCOG6G61 Final Report. Int J Radiat Oncol Biol Phys 18: 321–324, 1990
Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Eng J Med 332(15): 1004–1014, 1995
Chamberlain MC, Kormanik P: Salvage chemotherapy with Paclitaxel for recurrent primary brain tumors. J Clin Oncol 13: 2066–2071, 1995
Chamberlain MC, Kormanik PA: Salvage Chemotherapy with Paclitaxel for Recurrent Oligodendrogliomas. J Clin Oncol 15: 3427–3432, 1997
Glantz MJ, Choy H, Kearns CM, et al.: Phase I study of weekly outpatient Paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 14(2): 600–609, 1996
Fetell MR, Grossman SA, Balmaceda C, et al.: Clinical and pharmacologic study of pre-irradiation Taxol administered as a 96 hour infusion in adults with newly diagnosed glioblastoma multiforme. Proc ASCO 13: 179, 1994 (abstract)
Macdonald DR, Cascino TL, Schold Jr. SC, Cairncross JG: Response criteria for Phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7): 1277–1280, 1990
Grant R, Liang BC, Slattery MSc, Greenberg HS, Junck L: Chemotherapy Response Criteria in Malignant Glioma. Neurology 48: 1336–1340, 1997
Chamberlain MC, Kormanik PA: Salvage Chemotherapy with Tamoxifen for Recurrent Anaplastic Astrocytomas (AA). Neurology 50(4) Supplement 4: A382, 1998 (abstract).
Grant R, Liang BC, Page MA, et al.: Age influences chemotherapy response in astrocytomas. Neurology 45: 929–933, 1995
Burger PC, Green SB: Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59: 1617–1625, 1987
Prados MD, Gutin PH, Phillips TL, et al.: Highly anaplastic astrocytoma: A review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 23: 3–8, 1992
Cairncross JG, Eisenhauer EA: Response and control: Lessons from oligodendrogliomas. J Clin Oncol 13(9): 2475–2476, 1995 (Letter to the Editor)
Mason WP, Grovas A, Halpern S, et al.: Intensive Chemotherapy and Bone Marrow Rescue for Young Children with Newly Diagnosed Malignant Brain Tumors. J Clin Oncol 16: 210–221, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chamberlain, M.C., Kormanik, P. Salvage Chemotherapy with Taxol for Recurrent Anaplastic Astrocytomas. J Neurooncol 43, 71–78 (1999). https://doi.org/10.1023/A:1006277631745
Issue Date:
DOI: https://doi.org/10.1023/A:1006277631745